The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Different clinical outcome of metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to KRAS genotype and disease extension.
Gemma Bruera
No relevant relationships to disclose
Katia Cannita
No relevant relationships to disclose
Daniela Di Giacomo
No relevant relationships to disclose
Aude Lamy
No relevant relationships to disclose
Giancarlo Troncone
No relevant relationships to disclose
Antonella Dal Mas
No relevant relationships to disclose
Gino Coletti
No relevant relationships to disclose
Thierry Fr├ębourg
No relevant relationships to disclose
Jean-Christophe Sabourin
No relevant relationships to disclose
Mario Tosi
No relevant relationships to disclose
Corrado Ficorella
No relevant relationships to disclose
Enrico Ricevuto
No relevant relationships to disclose